A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event ACCLAIM-Lp(a)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.